Lexicon Pharmaceuticals, Inc.
Industry
- Pharmaceuticals
- Vaccines
- Biotechnology
- Drug Discovery Technologies
- Genomics-Proteomics
- Drug Discovery Technologies
Latest on Lexicon Pharmaceuticals, Inc.
In its sixth cardiometabolic disease deal of 2025, Novo Nordisk – reportedly concerned about its standing in the obesity and diabetes space versus its nearest rival, Eli Lilly – will turn to Deep Ap
Novo Nordisk has once again demonstrated its drive to stay on top in obesity, unveiling its second licensing deal in a matter of days. It will pay $75m upfront for rights to Lexicon’s LX9851, a first-
Lexicon Pharmaceuticals presented its Phase IIb data for pilavapadin (LX9211) on 3 March as a win that clarified the dosing regimen to take into Phase III in diabetic peripheral neuropathic pain (DPNP
Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP). If that trial r